Reliability of immunolabelling in the determination of Huntington's disease neuropathy | Zendy

Janelle Ashton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reliability of immunolabelling in the determination of Huntington's disease neuropathy

Author(s) -

Janelle Ashton

Publication year - 2011

Publication title -

brain

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.142

H-Index - 336

eISSN - 1460-2156

pISSN - 0006-8950

DOI - 10.1093/brain/awr091

Subject(s) - huntington's disease , endocannabinoid system , synaptophysin , cannabinoid receptor , cannabinoid , disease , tetrahydrocannabinol , neuroscience , medicine , receptor , biology , immunohistochemistry , agonist

Sir, The comprehensive analysis of striatal cannabinoid receptors in Huntington's disease by Blazquez et al ., 2011 raises some important issues of methodology. One major part of the study is the effect of CB1 receptor activation by Δ9-tetrahydrocannabinol (THC) on Huntington's disease neuropathy. To do this, the authors compare tissue derived from R6/2 mice treated either with THC or vehicle only. For each marker investigated in Fig. 4 (GAD67, synaptophysin and PSD95), THC treatment is shown to reverse loss …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research